Engineering and design software provider PTC (NASDAQ:PTC) will be reporting earnings tomorrow afternoon. Here’s what to ...

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) shot up 6.1% during trading on Monday after Cantor Fitzgerald raised their price target on the stock from $76.00 to $113.00. Cantor ...

Inc., a leading provider of software solutions for product design, manufacturing, and service, continues to navigate a challenging macroeconomic environment while positioning itself for future growth.

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

UBS analysts downgraded Calumet Specialty Products Partners' stock, traded on (NASDAQ:CLMT), from Neutral to Sell, setting ...

Below is Validea's guru fundamental report for PTC INC (PTC). Of the 22 guru strategies we follow, PTC rates highest using our P/B Growth Investor model based on the published strategy of Partha ...

Cantor Fitzgerald's analysts demonstrated a positive outlook on PTC Therapeutics (NASDAQ:PTCT), increasing the price target to $113.00 from the previous $76.00. The firm maintains an Overweight rating ...

Investors and market watchers will likely monitor PTC Therapeutics (NASDAQ:PTCT) closely to see if the company's performance aligns with Cowen's projections and to gauge the potential impact of this ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned a consensus rating of “Hold” from the fifteen research ...